ArticleHeliyon2025
Analysis of blood migration components in rats treated with Shaoyao Gancao Decoction using UPLC-Q-TOF-MS/MS.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the role and therapeutic applications of traditional Chinese medicine in radiation enteropathy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the prototype components and metabolites at different time points in the serum of rats after oral administration with Shaoyao Gancao Decoction (SGD), and to analyze their metabolism regularities in vivo. The UPLC-Q-TOF-MS/MS method was used to analyze the drug-containing serum samples at different time points. The mass spectrometry data were preliminarily processed using Analyst® TF 1.7.1 Software, followed by advanced analysis and visualization by PeakView 2.0 and Masterview1.0 to determine the retention time and relevant details of prototype components and metabolites. The MetabolitePilot™1.5 was employed to analyze the prototype components and metabolites in drug-containing serum samples at different time points, systematically summarizing their in vivo metabolic profiles. A total of 79 prototype components and 527 metabolites were detected in serum samples collected at 10 different time points, including flavonoids, terpenoids, volatile oils, organic acids, alkaloids, coumarins, etc. Of these, 11 prototype components were detected at all time points in the positive ion mode, and 19 were detected in the negative ion mode. Specifically, seven key components, including glycyrrhetinic acid, isoglycyrrhetinic acid, macedonic acid, diisobutyl phthalate, dibutyl phthalate, vitexin, and linoleic acid, were detected in both ion modes. This article is the first to analyze the metabolites of drug-containing serum at 10 different time points. The predominant metabolic processes in vivo included oxidation, reduction, hydrolysis, glucuronidation, sulfation, acetylation, methylation, and amino acid conjugation. The study revealed detailed data about the effective substances in SGD having a potential protective role against liver injury, which will support further investigation of the effective ingredient group of SGD and associated mechanism(s).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.